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characteristics”It is estimated that bladder cancer is the 7th and 17th most com-
mon cancer among men and women, respectively.1 The mortality
caused by bladder cancer is still a worldwide problem with esti-
mates suggesting 150,000 deaths annually.2 The majority of
bladder cancers are urothelial carcinoma and their risk factor
has been linked to the exposure of environmental carcinogen.
These carcinogens include tobacco,3,4 arsenic,5,6 aromatic
amines,7e10 and chlorinated water.11 Although many of these car-
cinogens are known to increase the risk of bladder cancer, the pre-
cise mechanism involved in the carcinogenesis is still not fully
elucidated. Yeh et al described the clinicopathological features of
bladder cancer in patients with arsenic exposure12. They found
that patients living in arsenic epidemic core areas had signiﬁcantly
shorter overall and cancer-speciﬁc survival duration compared
with patients in other areas. The information presented in their
study could help us understand the pathogenesis of arsenic-
associated bladder cancer and develop a better treatment algo-
rithm for this group of patients.
With the advancement in the ﬁeld of genomic medicine, such as
the application of the next-generation sequencing, potential mech-
anisms involved in the pathogenesis of various cancers have been
identiﬁed. Recent reports show that aristolochic acid (AA) induces
highly distinctive mutation signatures [predominant A/T trans-
versions and (CjT)AG/ (CjT)TG context] in the genomes of upper
urinary tract urothelial cell carcinomas.13,14 Interestingly, this
unique genetic signature can also be found in bladder cancer.15 By
knowing this unique AA-mutation signature, methods can be
developed to identify patients who may have higher risk of recur-
rence because of their exposure to this carcinogen. At present, there
are no genetic proﬁling data for arsenic-related bladder cancer.
However, Martinez et al16 showed that a uniquemutation signature
can be detected in arsenic-related lung cancer cases. They showed
that a lower number of point mutations was seen in this cancer but
with predominant T/G/A/C mutations. Therefore, it would be of
interest to study whether such mutation also occurs in the arsenic-
related bladder cancer. Besides environmental carcinogens, there
are endogenous mutagenic processes that play a role in cancer
development. The DNA cytidine deaminase APOBEC3B has been
involved in many cancer pathogeneses including bladder cancer,
and unique APOBEC-mutation signature with predominance of
C/G and C/T mutation and TC(AjT) context has also been
reported.17http://dx.doi.org/10.1016/j.urols.2015.05.003
1879-5226/Copyright © 2015, Taiwan Urological Association. Published by Elsevier TaiwGenetic signature is now applied in molecular epidemiology to
identify carcinogens that may be linked to a cancer. With this
knowledge, the risk factor that is involved in an individual's cancer
can be easily identiﬁed. This emerging ﬁeld will certainly have a
major impact on cancer prevention and treatment.
Conﬂicts of interest
The author declares that he has no ﬁnancial or non-ﬁnancial
conﬂicts of interest related to the subject matter or materials dis-
cussed in the manuscript.
Sources of Funding
No funding was received for the work described in the article.References
1. Kakehi Y, Hirao Y, Kim W-J, Ozono S, Masumori N, Miyanaga N, et al. Bladder
cancer working group report. Jpn J Clin Oncol 2010;40:i57e64.
2. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics.
CA Cancer J Clin 2011;61:69e90.
3. Brennan P, Bogillot O, Cordier S, Greiser E, Schill W, Vineis P, et al. Cigarette
smoking and bladder cancer in men: a pooled analysis of 11 case-control
studies. Int J Cancer 2000;86:289e94.
4. Howe GR, Burch JD, Miller AB, Cook GM, Esteve J, Morrison B, et al. Tobacco use,
occupation, coffee, various nutrients, and bladder cancer. J Natl Cancer Inst
1980;64:701e13.
5. Bates MN, Smith AH, Hopenhayn-Rich C. Arsenic ingestion and internal can-
cers: a review. Am J Epidemiol 1992;135:462e76.
6. Hopenhayn-Rich C, Biggs ML, Fuchs A, Bergoglio R, Tello EE, Nicolli H, et al.
Bladder cancer mortality associated with arsenic in drinking water in
Argentina. Epidemiology 1996;7:117e24.
7. Ward E, Carpenter A, Markowitz S, Roberts D, Halperin W. Excess number of
bladder cancers in workers exposed to ortho-toluidine and aniline. J Natl Can-
cer Inst 1991;83:501e6.
8. Ward EM, Sabbioni G, DeBord DG, Teass AW, Brown KK, Talaska GG, et al.
Monitoring of aromatic amine exposures in workers at a chemical plant with
a known bladder cancer excess. J Natl Cancer Inst 1996;88:1046e53.
9. Baan R, Straif K, Grosse Y, Secretan B, El Ghissassi F, Bouvard V, et al. Carcino-
genicity of some aromatic amines, organic dyes, and related exposures. Lancet
Oncol 2008;9:322e3.
10. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans.
Chemical agents and related occupations. IARC Monogr Eval Carcinog Risks
Hum 2012;100: 9e562.
11. Villanueva CM, Fernandez F, Malats N, Grimalt JO, Kogevinas M. Meta-analysis
of studies on individual consumption of chlorinated drinking water and
bladder cancer. J Epidemiol Community Health 2003;57:166e73.an LLC. Open access under CC BY-NC-ND license. 
Editorial comment / Urological Science 26 (2015) 109e11011012. Yeh TC, Tai YS, Pu Ys, Chen CH. Characteristics of arsenic related Bladder can-
cer: a study from national cancer registry Database in Taiwan. Urological Sci-
ence 2015;26:103e8.
13. Poon SL, Pang ST, McPherson JR, Yu W, Huang KK, Guan P, et al. Genome-wide
mutational signatures of aristolochic acid and its application as a screening
tool. Sci Transl Med 2013;5:197ra101.
14. Hoang ML, Chen CH, Sidorenko VS, He J, Dickman KG, Yun BH, et al. Mutational
signature of aristolochic acid exposure as revealed by whole-exome
sequencing. Sci Transl Med 2013;5:197ra102.
15. Poon SL, Huang MN, Choo Y, McPherson JR, Yu W, Heng HL, et al. Mutation sig-
natures implicate aristolochic acid in bladder cancer development. Genome
Med 2015;7:38.
16. Martinez VD, Thu KL, Vucic EA, Hubaux R, Adonis M, Gil L, et al. Whole-genome
sequencing analysis identiﬁes a distinctive mutational spectrum in an arsenic-
related lung tumor. J Thorac Oncol 2013;8:1451e5.
17. Burns MB, Temiz NA, Harris RS. Evidence for APOBEC3B mutagenesis in multi-
ple human cancers. Nat Genet 2013;45:977e83.See-Tong Pang*
Division of Urology, Department of Surgery, Chang Gung Memorial
Hospital (Linkou Branch), Chang Gung University, Taoyuan, Taiwan
* Division of Urology, Department of Surgery, Chang Gung
Memorial Hospital (Linkou Branch), Chang Gung University,
Number 5, Fushing Street, Kweishan, Taoyuan 333, Taiwan.
E-mail address: jacobpang@cgmh.org.tw.
5 May 2015
Available online 21 June 2015
